Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MPDL3280A · 1 trial · 2 indications
Time to toxicity defined as any grade 3, 4 regimen-related non-hematologic toxicity, during the first 15 weeks of therapy. The method of Thall et al. used for safety monitoring.
| Arm | Type | Description |
|---|---|---|
| Group 1: Chemotherapy + Radiation | EXPERIMENTAL | Participants receive standard chemotherapy and radiation for 6-7 weeks, followed by a 3-4 week rest period when they receive no chemotherapy or radiation. Consolidation Phase: After the rest period, participants receive MPDL3280A in addition to chemotherapy for 2 cycles. Maintenance Phase: After completing the consolidation period, participants continue to receive MPDL3280A alone for up to 1 year. |
| Group 2: MPDL3280A + Chemotherapy + Radiation | EXPERIMENTAL | Participants receive MPDL3280A, standard chemotherapy, and radiation therapy for 6-7 weeks. This will be followed by a rest period of 3-4 weeks, during which time participant receives 1 dose of MPDL3280A but no chemotherapy or radiation. Consolidation Phase: After the rest period, participants receive MPDL3280A in addition to chemotherapy for 2 cycles. Maintenance Phase: After completing the consolidation period, participants continue to receive MPDL3280A alone for up to 1 year. |
| Name | Type | Description |
|---|---|---|
| MPDL3280A | DRUG | 1200 mg by vein every 3 weeks up to 1 year after completing consolidation chemotherapy. Group 1: MPDL3280A given after receiving standard chemotherapy and radiation for 6-7 weeks, followed by a 3-4 week rest period. Group 2: MPDL3280A given with standard chemotherapy, and radiation therapy for 6-7 weeks followed by a rest period of 3-4 weeks, during which time participants receive 1 dose of MPDL3280A but no chemotherapy or radiation. |
| Carboplatin | DRUG | AUC 2 by vein once a week on Day 1 during radiation therapy. During consolidation chemotherapy, Carboplatin given at AUC 6 by vein on Days 1 and 22 for 2 cycles. |
| Paclitaxel | DRUG | 50 mg/m2 by vein once a week on Day 1 during radiation therapy. During consolidation chemotherapy, Paclitaxel given at 200 mg/m2 on Days 1 and 22 for 2 cycles. |
| Radiation Therapy | RADIATION | 60-66 Gy in 30-33 fractions administered once-daily on Day 1, 5 days a week, for 6 to 7 weeks. |
Inclusion Criteria: 1. Ability and willingness to provide informed consent 2. Ability and willingness to comply with the requirements of the study protocol 3. Age \>/= 18 years. 4. Representative tumor specimens in paraffin blocks (preferred) or at least 10 unstained slides, with an associated path...
Top 20 of 76 competitors
MPDL3280A is an investigational small molecule being studied for the treatment of lung cancer, specifically non-small cell lung cancer. It is currently in Phase 2 clinical development as a monotherapy or in combination with chemoradiation. The drug is being evaluated in a controlled clinical trial in the United States.
MPDL3280A is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting a Phase 2 clinical trial to evaluate the drug in patients with lung cancer, including non-small cell lung cancer.
MPDL3280A is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials. The ongoing Phase 2 trial is active but not recruiting participants.
MPDL3280A is being studied in a Phase 2 clinical trial with the identifier NCT02525757, titled 'MPDL3280A With Chemoradiation for Lung Cancer.' This trial is enrolling patients with lung cancer and non-small cell lung cancer in the United States, with a target enrollment of 52 participants.
MPDL3280A is also known as atezolizumab, an investigational cancer immunotherapy. In the context of this clinical trial, it is being evaluated for the treatment of lung cancer. The drug is being developed by Roche Holding AG under the brand name Tecentriq.